From Genes to Personalized Cancer Care: A Systematic Review of Toxicity-Associated Genetic Variants in Solid Tumor Treatments
Gonzalez-Hernandez, A.; Escamilla-Sanchez, A.; Perez-Ruiz, E.; Rios, A.; Frecha, C. A.; Vaca-Paniagua, F.; Barragan, I.; Perdomo, S.; Rueda-Dominguez, A.; oliver, j.
Show abstract
BackgroundPharmacogenomics has emerged as a crucial tool in precision medicine, offering the potential to personalise cancer treatments by predicting and managing therapy-induced toxicities. This systematic review examined the genetic basis of toxicities associated with radiotherapy, chemotherapy, and immunotherapy in solid tumours. MethodsA comprehensive literature search was conducted across PubMed, Google Scholar, and PharmKB databases, covering the period from December 2019 to July 2024. This review focused on genetic variants linked to different treatment-related toxicities, including chemotherapy, radiotherapy, and immunotherapy, across various solid tumour types. ResultsThe review primarily assessed immune-related adverse events and dermatologic, haematologic, neurological, and organ-specific toxicities (e.g. ototoxicity, hepatotoxicity, nephrotoxicity, and cardiotoxicity). This review highlights single-nucleotide variants (SNVs) as essential genetic markers for identifying treatment-related toxicities. However, data on many SNVs remains limited, highlighting the need for further research and clinical validation. These findings suggest that the understanding of genetic factors that contribute to toxicity may support treatment decisions, optimise patient outcomes, and promote advances in the field of precision oncology. ConclussionThe identification of specific genetic variants could prevent the use of expensive and ineffective treatments and guide the selection of patients most likely to benefit from a specific therapy. Here, we provide valuable insights into the current state of knowledge regarding the genetic basis of toxicity in solid tumour treatments and emphasise the importance of integrating pharmacogenomics into personalised cancer care. To enhance patient outcomes and reduce the economic burden of cancer treatment, further research must validate these genetic markers and integrate the findings into clinical practice, thereby avoiding ineffective treatments for patients.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Meta-Analysis of Adenoviral p53 Gene Therapy Clinical Trials in Recurrent Head and Neck Squamous Cell Carcinoma 94%
- mTOR inhibitors as radiosensitizers in neuroendocrine neoplasms 92%
- A pro-oxidant combination of resveratrol and copper down-regulates hallmarks of cancer and immune checkpoints in patients with advanced oral cancer: Results of an exploratory study (RESCU 004) 92%
Similar papers in this journal
- Genomic profile in TGCT Mexican patients reveals a potential biomarker of sensitivity to platinum-based therapy 92%
- KRAS mutations impact clinical outcome in metastatic non-small cell lung cancer 91%
- Drug-adapted cancer cell lines reveal drug-induced heterogeneity and enable the identification of biomarker candidates for the acquired resistance setting 91%
Similar papers in this journal
- Integrated single cell and bulk multi-omics reveals heterogeneity and early changes in pathways associated with cetuximab resistance in HNSCC sensitive cell lines 90%
- Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting 90%
- Pan-cancer analysis of pyrimidine metabolism reveals signaling pathways connections with chemoresistance role 89%
Similar papers in this journal
- COVID-19 Outcomes in Patients with Cancer: Findings from the University of California Health System Database 90%
- Compassionate use of recombinant human IL-7-hyFc as a salvage treatment for restoring lymphopenia in patients with recurrent glioblastoma 90%
- Added-value of whole exome and RNA Sequencing in advanced and refractory cancer patients with no molecular-based treatment recommendation based on a 90-gene panel 89%
Similar papers in this journal
- Study Protocol of A Phase II Study to Evaluate Safety and Efficacy of Neo-adjuvant Pembrolizumab and Radiotherapy in Localized Rectal Cancer 92%
- Feasibility of Administering Human Pancreatic Cancer Chemotherapy in a Spontaneous Pancreatic Cancer Mouse Model 92%
- Gene networks and expression quantitative trait loci associated with platinum-based chemotherapy response in high-grade serous ovarian cancer 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.